The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target.

Abstract

INTRODUCTION:

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies production and immune complex deposition with systemic clinical manifestations. Interleukin (IL)-17-producing cells play a crucial role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update on the possibility of targeting IL-17 in SLE. The rational for this approach as well as currently available and future targets are discussed. Expert opinion: Although human expression studies and animal models indicate that IL-17 blocking may be a promising therapeutic strategy for SLE, direct evidence for IL-17 inhibition in SLE patients is unavailable. Biologic therapies and small-molecule drugs that target IL-17 production are required for the achievement of a favorable clinical effect in SLE patients.

• Authors: Tomohiro Koga, Kunihiro Ichinose, Atsushi Kawakami, George C Tsokos
• Journal: Expert review of clinical immunology (Expert Rev Clin Immunol) Vol. 15 Issue 6 Pg. 629-637 (06 2019) ISSN: 1744-8409 [Electronic] England
• PMID: 30874446 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Interleukin-17

Topics

• Animals
• Disease Models, Animal
• Humans
• Interleukin-17 (antagonists & inhibitors, immunology)
• Lupus Erythematosus, Systemic (drug therapy, immunology, pathology)
• Th17 Cells (immunology, pathology)